期刊文献+

度鲁特韦的合成工艺优化研究 被引量:6

Research on optimization for synthetic process of dolutegravir
下载PDF
导出
摘要 以4-甲氧基乙酰乙酸甲酯为原料,经过六步反应合成了度鲁特韦关键中间体6,总体收率为18. 7%。六步反应中,仅仅在第四步和第六步通过洗涤滤饼的简单操作纯化了目标产物,其余步骤均采用粗产品进行下一步投料,极大地简化操作。通过对中间物7以及度鲁特韦终产物进行了重结晶纯化操作,提高了度鲁特韦原料药的纯度。 The key intermediate 6 of dolutegravir was synthesized through 6 steps of reaction starting from methyl 4-methoxyacetoacetate as raw material. The total yield of the 6 steps was up to 18.7%. In the above steps,only the products of the fourth and sixth step were purified through simply washing filter cake, whereas the products of the rest steps were raw product without special purification for next step. Through recrystallization, the purity of final product dolutegravir was enhanced to meet the requirements of industrial production.
作者 王先恒 赵长阔 郭伟航 周亦琪 徐浪 WANG Xian-heng;ZAHO Chang-kuo;GUO Wei-hang;ZHOU Yi-qi;XU Lang(School of Pharmacy,Zunyi Medical University,Zunyi 563000,China)
出处 《化学研究与应用》 CAS CSCD 北大核心 2018年第11期1865-1870,共6页 Chemical Research and Application
基金 贵州省科技计划项目(黔科合SY[2015]3030)资助 遵义医学院招标课题([2013]F-680)资助
关键词 度鲁特韦 合成 关键中间体 工艺优化 dolutegravir synthesis key intermediate process optimization
  • 相关文献

参考文献6

二级参考文献38

  • 1ZHANG L, RAMRATNAM B, TENNER- RACZ K, et al. Quantifying residual HIV- 1 replication in patients receiving combination antiretroviral therapy[J]. N Engl J Med, 1999, 340 (21) : 1605-1613.
  • 2Union Nation AIDS. 2012 China AIDS response progress report [EB/OL]. (2012-03-31)[2013-08-10]. http://www.unaids.org/ en / dataanalysis / knowyourresponse / countryprogressreports / 2012 countries/ce CN Narrative_Report[1].pdf.
  • 3POMMIER Y, JOHNSON AA, MAREHAND C. Integrase inhibitors to treat HIV/AIDS[J]. Nat Rev Drug Discov, 2005, 4 (3) : 236-248.
  • 4U.S. Food and Drug Administration. FDA approval of isentress (raltegravir)[EB/OL]. (2010-10-12) [2013-08-15]. http://www. fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVand AIDSActivities/ucm 124040.htm.
  • 5OPAR A. New HIV drug classes on the horizon[J]. Nat Rev Drug Diseov, 2007, 6(4): 258-259.
  • 6ERON JJ, COOPER DA, STEIGBIGEL RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo- controlled triMs[J]. Lancet Infect Dis, 2013, 13(7): 587-596.
  • 7国家食品药品监督管理总局.国家食品药品监督管理总局数据查询-进口化学药品[EB/OL].[2013-08-15].http:Happl.sfda.gov.cn/datasearch/faee3/base.jsp?tableld=36&tableName=TABLE36&title=%E8%BF%9B%E5%8F%A3%E8%8D%AF%E5%93%81&bcId=124356651564146415214424405468.
  • 8ELION R, MOLINA JM, ARRIBAS JR, et al. Efficacy and safety results from a randomized, double blind, active controlled trial of elvitegravir (once-daily) versus rahegravir (twice-daily) in treatment-experienced HIV-positive patients: long term 96- week data[EB/OL]. [2014-01-06]. http://iasociety.org/Abstracts/ A200744511.aspx.
  • 9MOLINA JM, LAMARCA A, JAIME AV. et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV- 1 receiving a ritonavir- boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study[J]. Lancet Infect Dis, 2012, 12(1): 27-35.
  • 10U.S. Food and Drug Administration. FDA approves new drug Tivicay (dolutegravir) to treat HIV infection[EB/OL]. (2013-08- 13) [2013 -08-15]. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm364744.htm.

共引文献28

同被引文献11

引证文献6

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部